Journal
BIOLOGY OF REPRODUCTION
Volume 103, Issue 2, Pages 390-399Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/biolre/ioaa122
Keywords
retinoic acid receptor; antagonists; selectivity; male contraception; mouse model; structure-activity relationships
Categories
Funding
- National Institute of Child Health and Human Development [U01-HD060479, U54-HD093540/P50-HD093540, HHSN275201300017C]
Ask authors/readers for more resources
Retinoic acid receptor alpha (RARA), a nuclear receptor protein, has been validated as a target for male contraception by gene knockout studies and also pharmacologically using a pan-retinoic acid receptor antagonist. Retinoic acid receptor alpha activity is indispensable for the spermatogenic process, and therefore its antagonists have potential as male contraceptive agents. This review discusses the effects of systematic dosing regimen modifications of the orally bioavailable and reversible pan-antagonist BMS-189453 as well as studies with the alpha-selective antagonists BMS-189532 and BMS-189614 in a m urine model. We also provide an overview of structure-activity studies of retinoic acid receptor alpha antagonists that provide insight for the design of novel alpha-selective ligands.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available